About: Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 13 August 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2018 (uk) im August 2018 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'agostu de 2018 (ast) scientific article published on 13 August 2018 (en)
publication date	wds:Q58456995-298A6635-78D9-4C3A-8142-FDC136239694
publication date	2018-08-13 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58456995-454FD708-288B-4351-81A4-59A8B9843E54
language of work or name	English
cites work	wds:Q58456995-00505D09-2DC6-4CB9-AE8B-2B45DDC40C4D wds:Q58456995-00AAD46F-3C1F-4161-B1F5-7E3DC69DAE62 wds:Q58456995-0BD19A48-37EA-4B35-A8A6-E75D5BB0DD34 wds:Q58456995-0DF52556-EA38-47A7-A285-9D132A9AF61D wds:Q58456995-1F32A38D-A0D8-4EA4-AC3C-423E954042D2 wds:Q58456995-2DB97396-9198-4EDB-B99B-12B125D5A566 wds:Q58456995-2F03C2C8-45CD-4391-AC12-3FA8718FCEDC wds:Q58456995-5246CCE7-F0FF-43D5-A871-8E063665B58D wds:Q58456995-54CA466C-CE49-4C16-BA99-2BD5403C49E8 wds:Q58456995-627574FD-9FD0-45FA-92A8-63511B897F5F wds:Q58456995-64C05174-0EDF-41E0-A0CB-BF93AED1D80F wds:Q58456995-6A989327-C86E-44FB-B9B8-613A5B9F6DCA wds:Q58456995-6DE4309C-1C89-4000-9899-EA5572295EA8 wds:Q58456995-74534E0D-FE2D-4C42-9D8D-82D2126EDFDD wds:Q58456995-75E807AC-FCCC-4A4A-9228-E47E4F17ECD8 wds:Q58456995-7D3FB92C-B33B-4E0B-BC29-3F2CC33D0B2E wds:Q58456995-7E3F66AF-8A5C-4959-AE33-F17E5D90EBBE wds:Q58456995-80146472-052C-4E58-855C-6C9FA80AED4E wds:Q58456995-A1226C80-996C-4CE8-B797-25AECBCAA2F1 wds:Q58456995-A1648D96-63A7-4122-9D67-32C88F0B6CF7 wds:Q58456995-A8AE8C0C-AFA5-4D8B-980D-76EF25FA5536 wds:Q58456995-B7E0161F-73BF-40C7-A548-B2B05591ABDE wds:Q58456995-BBC359BF-4822-44EF-8866-F1027D1669BA
cites work	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. The analysis of survival data: the Kaplan-Meier method Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias Comment on American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1):S1-S135 Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial. Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study.
author name string	wds:Q58456995-90135CAA-5666-41DC-908C-0790F2B422ED wds:Q58456995-E81F9A6D-3E22-4EB1-AA52-AB06A3E69046 wds:Q58456995-FF6DE7B4-2CD0-4CA3-8AFD-8F1BD21A235D
author name string	Josep Vidal Riccardo Perfetti Minzhi Liu
rdfs:label	Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes (en) Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (nl)
skos:prefLabel	Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes (en) Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (nl)
name	Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes (en) Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (nl)
author	wds:Q58456995-019DA221-31CC-48CE-85E8-85A49AF43C8E wds:Q58456995-42DC0837-D196-433D-BEF4-74E7411D004C wds:Q58456995-6CFC52EB-02E0-41EE-93EF-E283CE708278 wds:Q58456995-9D8F8418-0030-45B6-8BAB-8C4867BF2E82 wds:Q58456995-A0C5FD16-668D-4B8F-8867-06DAF95530AF
author	Francesco Giorgino Yehuda Handelsman Julio Rosenstock Juris J Meier Francisco Javier Ampudia Blasco
title	wds:Q58456995-639AFEF1-0B0F-4335-8D8C-7073A866DA72
title	Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes (en)
page(s)	wds:Q58456995-F1CD8FC4-9108-4F83-80F0-D983B94E9072
page(s)	2821-2829
instance of	wds:Q58456995-48A42B6C-11D9-47B5-AEBE-51001B856616
instance of	scholarly article
main subject	wds:Q58456995-717BF5AD-AFDD-4317-BBCA-5B3253C9D598 wds:Q58456995-8F2DB2E7-AF24-454D-A724-70306BF21996 wds:Q58456995-A3C085AB-AB8A-4FE7-91E9-C7ED04738F72 wds:Q58456995-D63A782A-C218-4740-9F63-1661813FC909
main subject	insulin glargine endocrinology wd:Q7240673 type 2 diabetes
PubMed ID	wds:Q58456995-C13920F5-A8E9-4380-B690-384F2A04D677
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/29974618
PubMed ID	29974618
published in	wds:Q58456995-EA04C620-004A-4094-8E82-CE5254FBE7C9
published in	Diabetes, Obesity and Metabolism
issue	wds:Q58456995-D69636C2-418F-46E9-8BE8-C65AEEE37C1D
volume	wds:Q58456995-5D38025E-25F3-49CA-9E76-088C189FD99E
issue	12

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software